Is Retatrutide Safe While Breastfeeding? What Nursing Mothers Need to Know

What Is Retatrutide and Why Are Women Asking About It?

Retatrutide is a once-weekly injectable peptide that activates three receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. That triple mechanism sets it apart from semaglutide (GLP-1 only) and tirzepatide (GLP-1 and GIP), and early phase 2 trial data are generating real excitement.

In the NEJM phase 2 trial published in 2023, participants taking the highest retatrutide dose (12 mg weekly) lost a mean of 24.2% of body weight at 48 weeks. That number exceeds what has been reported with any other approved obesity pharmacotherapy to date. Women made up roughly half of that trial population, and the weight-loss magnitude in female participants was comparable to the overall cohort, though the trial was not powered to detect sex-specific differences.

Because postpartum weight retention affects a large proportion of women, and because many new mothers are already aware of GLP-1 medications from mainstream coverage, questions about using retatrutide during breastfeeding are arriving at clinicians' desks before the drug has even cleared FDA review.

Why Postpartum Women Are Particularly Interested

Postpartum weight retention of more than 5 kg at six months affects an estimated 20% of women after their first birth, and that retained weight is a documented risk factor for long-term obesity. The drive to find effective pharmacological support is understandable. Breastfeeding itself does not reliably produce clinically significant weight loss for most women, despite common belief to the contrary. Against that backdrop, a drug showing 24% weight loss in 48 weeks is going to attract interest from nursing mothers.

The problem is the data simply do not exist yet to call it safe.

Retatrutide's Current Regulatory and Development Status

Retatrutide is being developed by Eli Lilly. As of early 2025, it has not received FDA approval for any indication. Phase 3 trials (the TRIUMPH program) are ongoing for obesity and type 2 diabetes. No FDA-approved prescribing label exists, which means there is no official pregnancy or lactation subsection in an approved label to reference.

What does exist: animal reproductive toxicity data submitted as part of the Investigational New Drug (IND) program, the phase 2 trial publication, and data from structurally related GLP-1 class drugs whose labels do carry pregnancy and lactation language. Clinicians and patients are therefore working from two imperfect sources: extrapolation from the drug class and from animal data.

The FDA's guidance on evaluating drugs in pregnancy and lactation requires sponsors to conduct reproductive toxicity studies in animals before human trials, but it does not require human lactation studies prior to approval. That regulatory structure means a drug can reach market without a single data point on breast milk transfer.

The GLP-1 Class as a Proxy (and Its Limits)

Semaglutide (Ozempic, Wegovy) is the most studied GLP-1 agonist. Its prescribing label states that use during breastfeeding is not recommended because of potential risks to the nursing infant, though no human breast milk studies have been published in peer-reviewed literature as of this writing. LactMed, the National Institutes of Health's drug-in-lactation database, notes for semaglutide that maternal use during breastfeeding is not recommended by the manufacturer, and that infant risk cannot be ruled out.

Retatrutide shares the GLP-1 receptor mechanism but adds GIP and glucagon receptor activity. Whether those additional mechanisms alter milk transfer, infant GI effects, or infant growth cannot be determined from existing class data alone. Extrapolating from semaglutide to retatrutide is reasonable as a precautionary framework, but it is extrapolation, not evidence.

Pregnancy and Lactation Safety: The Full Picture

This section is required for any drug article on WomanRx. What follows is every piece of relevant human and animal data currently available, stated plainly.

Animal Reproductive Toxicity Data

Animal studies for retatrutide and closely related GLP-1 receptor agonists consistently show dose-dependent fetal harm. In rat and rabbit embryo-fetal development studies conducted for liraglutide (a structural comparator and GLP-1 agonist), fetal malformations and early pregnancy losses occurred at exposures that overlap with the human therapeutic range. The FDA requires that the semaglutide label carry a warning stating the drug caused fetal harm in animal reproduction studies.

For retatrutide specifically, Eli Lilly has not publicly released detailed animal reproductive toxicity findings outside of regulatory submissions. Based on the class pattern, fetal harm at high exposures is biologically plausible. The glucagon receptor agonism component adds theoretical concern because glucagon influences hepatic glucose output and fetal metabolic signaling, though direct teratogenic data for glucagon agonism in humans do not exist.

Human Pregnancy Data

Zero. No published human pregnancy exposure data exist for retatrutide as of January 2025. Women of reproductive potential were required to use effective contraception and were excluded from the phase 2 trial if pregnant. Any pregnancy exposures that have occurred in the context of off-label or trial use have not been published.

ACOG's guidance on obesity pharmacotherapy makes clear that weight-loss medications in pregnancy carry significant uncertainty and that the general principle is to avoid pharmacological weight-loss interventions during pregnancy unless the risk-benefit calculation is clearly favorable, which it rarely is for this drug class.

Human Breastfeeding Data

None. There are no published data on retatrutide transfer into human breast milk, infant serum levels, or infant outcomes following maternal use. LactMed's entry for the GLP-1 class documents this absence and recommends against use during breastfeeding for approved agents in the class.

Retatrutide is a large peptide molecule (molecular weight approximately 4,700 daltons in its acylated form). Large molecules generally transfer into breast milk at lower rates than small molecules, and peptides are typically degraded by infant intestinal proteases before reaching systemic circulation. That pharmacokinetic argument is sometimes used to reassure patients, but it does not substitute for actual transfer and safety data. The half-life of retatrutide is approximately six days, meaning the drug persists in maternal plasma for weeks after the last dose. Even low milk-transfer rates could result in chronic low-level infant exposure over a full breastfeeding course.

Contraception Requirements

Because retatrutide causes fetal harm in animals and has no human pregnancy safety data, women of reproductive potential should use reliable contraception during treatment. A specific consideration: GLP-1 receptor agonists slow gastric emptying, which can reduce peak plasma concentrations of orally administered drugs, including combined oral contraceptive pills. The semaglutide label specifically notes this interaction. Women using oral contraceptives as their primary contraception method while on retatrutide (or any GLP-1 agonist) may have reduced pill efficacy during the first month of GLP-1 initiation or dose escalation. Barrier backup or switching to a non-oral method (IUD, implant, injectable) is a reasonable precaution.

A practical decision framework for women at the intersection of reproductive planning and retatrutide use:

| Life Stage | Recommendation | |---|---| | Actively trying to conceive | Do not start retatrutide; discuss alternatives | | Pregnant | Do not use; no safety data, animal harm signal | | Breastfeeding (exclusively) | Do not use; no lactation data, class contraindication | | Breastfeeding and planning to wean soon | Discuss timing with your clinician; washout period unclear | | Postpartum, not breastfeeding | May be a candidate when approved; discuss with clinician | | Perimenopause with past breastfeeding | Standard adult candidacy criteria apply |

What the Evidence Gap Means for You

Women have been systematically excluded from drug trials for decades, and that history matters here. Pregnant and breastfeeding women are almost universally excluded from phase 2 and phase 3 trials for obesity medications, leaving clinicians to counsel patients based on animal data and class extrapolation rather than evidence specific to their situation. A 2021 analysis in JAMA documented that fewer than 5% of clinical trial participants across major disease areas were pregnant or postpartum women. The result is that the people who most need guidance often have the least data to guide them.

For retatrutide, this gap is especially wide because the drug has not yet completed phase 3 trials in any population, let alone in reproductive-age women. The honest answer to "is retatrutide safe while breastfeeding" is: we do not know, and the absence of data is not the same as safety.

What Physicians Actually Say

Dr. Stephanie Faubion, Medical Director of The Menopause Society, has written broadly on the need to generate sex-specific data for obesity pharmacotherapy, noting that women metabolize GLP-1 class agents differently from men, with more nausea at equivalent doses and potentially different dose-response curves. While her comments address menopause-age women rather than postpartum specifically, the underlying principle applies: extrapolating population-level trial data to any specific female life stage carries meaningful uncertainty.

ACOG Committee Opinion 763 establishes the ethical principle that uncertainty about a drug's safety in breastfeeding should be resolved in favor of caution when the clinical indication (weight loss) is not immediately life-saving and alternatives exist.

Who Should Not Use Retatrutide (Life-Stage Framing)

Breastfeeding Women

Do not use retatrutide while breastfeeding. This recommendation applies regardless of how much weight you want to lose or how confident you feel about the drug based on its phase 2 results. The long half-life (approximately six days), the lack of any milk-transfer data, and the potential for chronic low-level infant GI exposure are sufficient reasons to wait.

Pregnant Women

Do not use retatrutide during pregnancy. Animal data suggest fetal harm. There are no human pregnancy data. If you become pregnant while on retatrutide, stop the drug and contact your obstetric provider.

Women Planning Pregnancy in the Near Term

Discuss stopping retatrutide at least two to three months before attempting conception to allow for washout, though no official pre-conception washout interval has been established for this drug. For comparison, the FDA-approved semaglutide label recommends stopping at least two months before planned pregnancy. Given retatrutide's similar or longer half-life, a comparable or longer interval is reasonable as a precaution.

Women in Perimenopause or Postmenopause

The absence of pregnancy-related restrictions does not apply here. Women who are no longer cycling and are not at risk of pregnancy face a different risk-benefit calculation. However, retatrutide remains investigational for all women in this group, too, until phase 3 data are published and FDA review is complete.

Safer Alternatives for Postpartum Weight Management

If you are breastfeeding and need support with postpartum weight, retatrutide is not your option right now. Here is what currently has more supporting evidence:

Dietary and Behavioral Strategies

A randomized trial by Lim et al. In Obesity (2022) found that structured dietary counseling starting at six weeks postpartum produced clinically meaningful weight loss without reducing milk supply, breastfeeding duration, or infant growth outcomes. This remains the first-line approach endorsed by ACOG's postpartum care guidance.

Metformin (PCOS or Insulin Resistance)

For women with PCOS who are breastfeeding and have insulin resistance driving weight retention, metformin is a considered option. LactMed documents that metformin transfers into breast milk at low levels, and available infant data have not shown adverse effects. This does not make it universally appropriate, but it represents a drug where actual lactation data exist, unlike retatrutide.

Approved GLP-1 Agents (With Caveats)

Semaglutide and liraglutide are not recommended during breastfeeding either, as discussed above. The data situation for those approved drugs is better than for retatrutide only in that a formal prescribing label exists, and the class risk is characterized rather than entirely unknown. Neither is a green light for nursing mothers.

What to Expect as Research Evolves

The TRIUMPH phase 3 program for retatrutide is ongoing. ClinicalTrials.gov lists multiple active studies, and FDA submission is anticipated within the next one to two years if results support it. An FDA approval will require a prescribing label with pregnancy and lactation subsections, which will crystallize the official recommendation.

Real-world post-marketing pregnancy registries, similar to those established for other GLP-1 agonists, may also generate human data faster than controlled trials. ACOG encourages enrollment in such registries for women who become inadvertently exposed to novel drugs during pregnancy.

Until that evidence base grows, the clinical position is consistent: retatrutide is not recommended during pregnancy or breastfeeding, and women who want to use it for weight management should wait until they have weaned, ensure reliable contraception, and review timing with their prescribing clinician.

Your postpartum body is not the same as your pre-pregnancy body in terms of hormonal environment, metabolic rate, or gut motility. A clinician who specializes in women's metabolic health can help you build a plan that fits where you actually are in your reproductive life, not just where a trial population was.